Keyword: Imfinzi (durvalumab)
Imfinzi already is I-O's only FDA-approved maintenance therapy in lung cancer. Friday, the AZ med hit another benchmark to stretch out that lead.
Crestor sales nosedived by 42% to $389 million in Q1, well below analyst estimates, but execs hope new cancer drugs can cushion the fall.
AstraZeneca slashed CEO Pascal Soriot’s total pay by 34% in 2017, but that cut wasn’t deep enough for one influential voice on corporate governance.
AstraZeneca has come up short in another lung cancer trial of its immuno-oncology combo.
BioMarin knows winning drug names. For the second time, one of its drugs won our #FierceMadness tournament—thanks in large part to BioMarin employees.
First rule of ballot stuffing? To avoid raising red flags, don't overdo it. And that’s exactly what 34,035 #FierceMadness votes for Brineura did.
The final showdown is set: BioMarin’s Brineura will face off against AstraZeneca’s Imfinzi in the drug name championship for 2018.
Under a 2003 agreement, Array BioPharma says AstraZeneca needs to pony up $192 million.
AstraZeneca's Imfinzi won't have its first-line lung cancer data till later than expected, and at a time when Merck's Keytruda is racing ahead.
BN's cancer vaccine CV301 is already under evaluation with Keytruda in NSCLC and with Tecentriq in bladder cancer.